Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials
The treatment of older people with hemophilia A (HA) can be complicated by comorbidities. This post hoc analysis evaluates the efficacy and safety of emicizumab in people with HA aged ≥50 years with cardiovascular (CV) risk factors or HIV and/or hepatitis C virus (HCV) infection. The HAVEN 1 (NCT026...
Saved in:
Published in | Research and practice in thrombosis and haemostasis Vol. 8; no. 3; p. 102405 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.03.2024
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The treatment of older people with hemophilia A (HA) can be complicated by comorbidities.
This post hoc analysis evaluates the efficacy and safety of emicizumab in people with HA aged ≥50 years with cardiovascular (CV) risk factors or HIV and/or hepatitis C virus (HCV) infection.
The HAVEN 1 (NCT02622321), HAVEN 3 (NCT02847637), HAVEN 4 (NCT03020160), and STASEY (NCT03191799) studies enrolled adults/adolescents with severe HA. Participants were categorized as having a comorbidity if they had any CV risk factors (including history of CV disease, hypertension, diabetes, hyperlipidemia, prior stroke, or obesity), HIV, and/or HCV infection. Efficacy and safety outcomes were compared by age (<50 vs ≥50 years).
Of 504 participants at data cutoff, 408 were aged <50 years and 96 were aged ≥50 years. In people with HA aged <50 years, 26.7% had ≥1 CV risk factor and 29.4% had HIV and/or HCV infection. In people with HA aged ≥50 years, 72.9% had ≥1 CV risk factor and 74.0% had HIV and/or HCV infection. The mean (95% CI) annualized bleed rate for treated bleeds was 1.29 (0.07-6.06) for people with HA aged <50 years and 1.82 (0.19-6.93) for people with HA aged ≥50 years. No significant differences in annualized bleed rates were observed for those with comorbidities compared with those without. Safety outcomes were similar regardless of age.
This pooled analysis suggests that emicizumab efficacy and safety in people with HA aged ≥50 years with CV and HIV/HCV comorbidities were consistent with those in people with HA aged <50 years enrolled in the HAVEN 1, 3, and 4 and STASEY studies.
•Older people with hemophilia A may have other diseases at the same time (comorbidities).•This analysis addresses the data gap of emicizumab in people with hemophilia A aged ≥50 years with comorbidities.•Emicizumab efficacy and safety were not adversely affected by comorbidities seen in older people with hemophilia A.•Outcomes in people with hemophilia A aged ≥50 years with comorbidities were similar to those in the population aged <50 years. |
---|---|
AbstractList | •
Older people with hemophilia A may have other diseases at the same time (comorbidities).
•
This analysis addresses the data gap of emicizumab in people with hemophilia A aged ≥50 years with comorbidities.
•
Emicizumab efficacy and safety were not adversely affected by comorbidities seen in older people with hemophilia A.
•
Outcomes in people with hemophilia A aged ≥50 years with comorbidities were similar to those in the population aged <50 years. The treatment of older people with hemophilia A (HA) can be complicated by comorbidities. This post hoc analysis evaluates the efficacy and safety of emicizumab in people with HA aged ≥50 years with cardiovascular (CV) risk factors or HIV and/or hepatitis C virus (HCV) infection. The HAVEN 1 (NCT02622321), HAVEN 3 (NCT02847637), HAVEN 4 (NCT03020160), and STASEY (NCT03191799) studies enrolled adults/adolescents with severe HA. Participants were categorized as having a comorbidity if they had any CV risk factors (including history of CV disease, hypertension, diabetes, hyperlipidemia, prior stroke, or obesity), HIV, and/or HCV infection. Efficacy and safety outcomes were compared by age (<50 vs ≥50 years). Of 504 participants at data cutoff, 408 were aged <50 years and 96 were aged ≥50 years. In people with HA aged <50 years, 26.7% had ≥1 CV risk factor and 29.4% had HIV and/or HCV infection. In people with HA aged ≥50 years, 72.9% had ≥1 CV risk factor and 74.0% had HIV and/or HCV infection. The mean (95% CI) annualized bleed rate for treated bleeds was 1.29 (0.07-6.06) for people with HA aged <50 years and 1.82 (0.19-6.93) for people with HA aged ≥50 years. No significant differences in annualized bleed rates were observed for those with comorbidities compared with those without. Safety outcomes were similar regardless of age. This pooled analysis suggests that emicizumab efficacy and safety in people with HA aged ≥50 years with CV and HIV/HCV comorbidities were consistent with those in people with HA aged <50 years enrolled in the HAVEN 1, 3, and 4 and STASEY studies. BackgroundThe treatment of older people with hemophilia A (HA) can be complicated by comorbidities.ObjectivesThis post hoc analysis evaluates the efficacy and safety of emicizumab in people with HA aged ≥50 years with cardiovascular (CV) risk factors or HIV and/or hepatitis C virus (HCV) infection.MethodsThe HAVEN 1 (NCT02622321), HAVEN 3 (NCT02847637), HAVEN 4 (NCT03020160), and STASEY (NCT03191799) studies enrolled adults/adolescents with severe HA. Participants were categorized as having a comorbidity if they had any CV risk factors (including history of CV disease, hypertension, diabetes, hyperlipidemia, prior stroke, or obesity), HIV, and/or HCV infection. Efficacy and safety outcomes were compared by age (<50 vs ≥50 years).ResultsOf 504 participants at data cutoff, 408 were aged <50 years and 96 were aged ≥50 years. In people with HA aged <50 years, 26.7% had ≥1 CV risk factor and 29.4% had HIV and/or HCV infection. In people with HA aged ≥50 years, 72.9% had ≥1 CV risk factor and 74.0% had HIV and/or HCV infection. The mean (95% CI) annualized bleed rate for treated bleeds was 1.29 (0.07-6.06) for people with HA aged <50 years and 1.82 (0.19-6.93) for people with HA aged ≥50 years. No significant differences in annualized bleed rates were observed for those with comorbidities compared with those without. Safety outcomes were similar regardless of age.ConclusionThis pooled analysis suggests that emicizumab efficacy and safety in people with HA aged ≥50 years with CV and HIV/HCV comorbidities were consistent with those in people with HA aged <50 years enrolled in the HAVEN 1, 3, and 4 and STASEY studies. The treatment of older people with hemophilia A (HA) can be complicated by comorbidities. This post hoc analysis evaluates the efficacy and safety of emicizumab in people with HA aged ≥50 years with cardiovascular (CV) risk factors or HIV and/or hepatitis C virus (HCV) infection. The HAVEN 1 (NCT02622321), HAVEN 3 (NCT02847637), HAVEN 4 (NCT03020160), and STASEY (NCT03191799) studies enrolled adults/adolescents with severe HA. Participants were categorized as having a comorbidity if they had any CV risk factors (including history of CV disease, hypertension, diabetes, hyperlipidemia, prior stroke, or obesity), HIV, and/or HCV infection. Efficacy and safety outcomes were compared by age (<50 vs ≥50 years). Of 504 participants at data cutoff, 408 were aged <50 years and 96 were aged ≥50 years. In people with HA aged <50 years, 26.7% had ≥1 CV risk factor and 29.4% had HIV and/or HCV infection. In people with HA aged ≥50 years, 72.9% had ≥1 CV risk factor and 74.0% had HIV and/or HCV infection. The mean (95% CI) annualized bleed rate for treated bleeds was 1.29 (0.07-6.06) for people with HA aged <50 years and 1.82 (0.19-6.93) for people with HA aged ≥50 years. No significant differences in annualized bleed rates were observed for those with comorbidities compared with those without. Safety outcomes were similar regardless of age. This pooled analysis suggests that emicizumab efficacy and safety in people with HA aged ≥50 years with CV and HIV/HCV comorbidities were consistent with those in people with HA aged <50 years enrolled in the HAVEN 1, 3, and 4 and STASEY studies. •Older people with hemophilia A may have other diseases at the same time (comorbidities).•This analysis addresses the data gap of emicizumab in people with hemophilia A aged ≥50 years with comorbidities.•Emicizumab efficacy and safety were not adversely affected by comorbidities seen in older people with hemophilia A.•Outcomes in people with hemophilia A aged ≥50 years with comorbidities were similar to those in the population aged <50 years. |
ArticleNumber | 102405 |
Author | Oldenburg, Johannes Jiménez-Yuste, Víctor Lim, Elise Sanabria, Fabian Mahlangu, Johnny Tzeng, Eunice |
Author_xml | – sequence: 1 givenname: Víctor orcidid: 0000-0003-3937-3499 surname: Jiménez-Yuste fullname: Jiménez-Yuste, Víctor email: vjimenezy@salud.madrid.org organization: Hematology Department, Hospital Universitario La Paz, IdiPAZ, Autónoma University, Madrid, Spain – sequence: 2 givenname: Johannes surname: Oldenburg fullname: Oldenburg, Johannes organization: Institute of Experimental Haematology and Transfusion Medicine, University of Bonn, Bonn, Germany – sequence: 3 givenname: Eunice surname: Tzeng fullname: Tzeng, Eunice organization: Genentech, Inc., South San Francisco, California, USA – sequence: 4 givenname: Elise surname: Lim fullname: Lim, Elise organization: Genentech, Inc., South San Francisco, California, USA – sequence: 5 givenname: Fabian surname: Sanabria fullname: Sanabria, Fabian organization: F. Hoffmann-La Roche Ltd, Basel, Switzerland – sequence: 6 givenname: Johnny surname: Mahlangu fullname: Mahlangu, Johnny organization: Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38783987$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kcFu1DAQhi1UREvpC3BAPnLZZWJn4wQhoaoqsFIlLnC2HHvczCqJg50tWt6AB-HFeBK8SqnKBcvSWONvflv__5ydjGFExl4WsC6gqN7s1nGau7UAUeaGKGHzhJ2JUm1WIFVz8uh8yi5S2gFAZvPePGOnsla1bGp1xg7XA1n6sR9Myylx9J6ssRT2idPIJwxTj_w7zR3vcAhTRz0Zfrl0bBhCbMnRTJi4uUXHf__8tQF-QBPTW25G0x9SVg2el3zqTEK-3W75HMn06QV76nPBi_t6zr5-uP5y9Wl18_nj9uryZmVLUPPKmFq51rkGZCkb2XowohZQgAffVEWJ4KUvUJRta1plPICrTONRVaqw1jt5zt4vutO-HdBZHOdoej1FGkw86GBI_3szUqdvw50u8hJSiazw-l4hhm97TLMeKFnsezNiNkpLqI4-10JlVCyojSGliP7hnQL0MTe908fc9DE3veSWh149_uHDyN-UMvBuATD7dEcYdbKEo0VHEe2sXaD_6f8Bl42uGQ |
Cites_doi | 10.1182/blood.2019001869 10.1182/bloodadvances.2018018226 10.1111/bjh.18085 10.1182/blood-2017-08-801662 10.1002/rth2.12837 10.1186/1750-1172-7-24 10.1161/ATVBAHA.111.238162 10.1111/jth.15189 10.1056/NEJMoa1803550 10.1160/TH12-05-0332 10.1016/j.advms.2018.06.001 10.1161/CIRCULATIONAHA.117.033369 10.1182/bloodadvances.2021005260 10.1182/blood.2020009217 10.1111/jth.13811 10.1007/s40265-019-01200-2 10.1111/j.1365-2141.2012.09134.x 10.1016/j.mcna.2011.11.003 10.1111/hae.12339 10.1097/JCMA.0000000000000047 10.1111/hae.14046 10.1111/bjh.15745 10.2214/AJR.14.12501 10.1016/S2352-3026(19)30054-7 10.1182/blood-2021-146147 10.1111/hae.14261 10.1182/blood-2019-123761 10.1001/jama.2013.184182 10.1111/hae.14013 10.1089/apc.2010.0104 10.1016/S2352-3026(22)00377-5 10.1160/TH17-01-0030 10.1182/blood-2009-07-215665 10.1056/NEJMoa1703068 10.1111/j.1365-2516.2010.02463.x |
ContentType | Journal Article |
Copyright | 2024 The Authors 2024 The Authors. 2024 The Authors 2024 |
Copyright_xml | – notice: 2024 The Authors – notice: 2024 The Authors. – notice: 2024 The Authors 2024 |
DBID | 6I. AAFTH NPM AAYXX CITATION 7X8 5PM |
DOI | 10.1016/j.rpth.2024.102405 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 2475-0379 |
EndPage | 102405 |
ExternalDocumentID | 10_1016_j_rpth_2024_102405 38783987 S2475037924000943 |
Genre | Journal Article |
GroupedDBID | .1- .FO 0SF 1OC 24P 53G 6I. 7X7 8FI 8FJ AAFTH AAHHS AAXUO ABUWG ACCFJ ACXQS ADBBV ADKYN ADZMN AEEZP AEQDE AFKRA AFRHN AITUG AIWBW AJAOE AJBDE AJUYK ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AMRAJ AOIJS AVUZU BCNDV BENPR BPHCQ BVXVI CCPQU EBS EJD FDB FYUFA GROUPED_DOAJ HMCUK HYE IAO IHR INH M41 M~E O9- OK1 PIMPY PQQKQ PROAC ROL RPM UKHRP WIN Z5R ZCN AALRI ADVLN AFJKZ AKRWK ITC NPM AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c407t-aa87dbdd9034393bf0a282010f0f9614e0f3f1e24bbab7af00d6a9fe7671ccfd3 |
IEDL.DBID | RPM |
ISSN | 2475-0379 |
IngestDate | Tue Sep 17 21:28:28 EDT 2024 Sat Aug 17 05:08:53 EDT 2024 Thu Sep 26 15:55:31 EDT 2024 Wed Oct 23 09:39:50 EDT 2024 Tue Jun 18 08:52:02 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | emicizumab hemophilia A comorbidity comorbidities prophylaxis |
Language | English |
License | This is an open access article under the CC BY license. 2024 The Authors. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c407t-aa87dbdd9034393bf0a282010f0f9614e0f3f1e24bbab7af00d6a9fe7671ccfd3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-3937-3499 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11112372/ |
PMID | 38783987 |
PQID | 3060379827 |
PQPubID | 23479 |
PageCount | 1 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_11112372 proquest_miscellaneous_3060379827 crossref_primary_10_1016_j_rpth_2024_102405 pubmed_primary_38783987 elsevier_sciencedirect_doi_10_1016_j_rpth_2024_102405 |
PublicationCentury | 2000 |
PublicationDate | 2024-03-01 |
PublicationDateYYYYMMDD | 2024-03-01 |
PublicationDate_xml | – month: 03 year: 2024 text: 2024-03-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Research and practice in thrombosis and haemostasis |
PublicationTitleAlternate | Res Pract Thromb Haemost |
PublicationYear | 2024 |
Publisher | Elsevier Inc Elsevier |
Publisher_xml | – name: Elsevier Inc – name: Elsevier |
References | Srivastava, Elena, Dougall, Kitchen, Sutherland, Pipe (bib1) 2020; 26 Misgav, Brutman-Barazani, Budnik, Avishai, Schapiro, Bashari (bib17) 2021; 27 Fransen van de Putte, Fischer, Makris, Tait, Chowdary, Collins (bib26) 2013; 109 Shapiro, Benson, Evans, Harrison, Mangles, Makris (bib27) 2022; 197 Mahlangu, Oldenburg, Paz-Priel, Negrier, Niggli, Mancuso (bib9) 2018; 379 Tuinenburg, Rutten, Kavousi, Leebeek, Ypma, Laros-van Gorkom (bib22) 2012; 32 Franchini, Mannucci (bib32) 2012; 7 Callaghan, Negrier, Paz-Priel, Chang, Chebon, Lehle (bib36) 2021; 137 Sharathkumar, Soucie, Trawinski, Greist, Shapiro (bib24) 2011; 17 Doria, Keshava, Mohanta, Jarrin, Blanchette, Srivastava (bib39) 2015; 204 Blair (bib4) 2019; 79 Garg, Hoenig, Edwards, Bliss, Heeren, Tumilty (bib30) 2011; 25 Manco-Johnson, Lundin, Funk, Peterfy, Raunig, Werk (bib38) 2017; 15 Oldenburg, Mahlangu, Kim, Schmitt, Callaghan, Young (bib8) 2017; 377 Papadopoulos, Argiana, Deutsch (bib29) 2018; 31 Négrier, Mahlangu, Lehle, Chowdary, Catalani, Bernardi (bib13) 2023; 10 Shapiro, Makris (bib2) 2019; 184 Recht, Mahlangu, Minhas, Trzaskoma, Shah, Young (bib14) 2021; 5 Chang, Li, Cheng, Pan, Cheng, Wang (bib21) 2019; 82 Pipe, Shima, Lehle, Shapiro, Chebon, Fukutake (bib10) 2019; 6 Sood, Cheng, Ragni, Kessler, Quon, Shapiro (bib19) 2018; 2 Kempton, Makris, Holme (bib23) 2021; 27 Faghmous, Flores, Sarouei, Chang, Patel, Sima (bib25) 2019; 134 Howard, McKinley, Sanabria, Ko, Nissen (bib40) 2021; 138 Humphries, Rule, Ogbonnaya, Eaddy, Lunacsek, Lamerato (bib20) 2018; 63 Jenkins, Rawley, Smith, O'Donnell (bib16) 2012; 157 Mannucci, Schutgens, Santagostino, Mauser-Bunschoten (bib33) 2009; 114 Lenting, Denis, Christophe (bib6) 2017; 130 Chow, Teo, Rangarajan, Islam, Gupta, Avezum (bib35) 2013; 310 Van Der Valk, Makris, Fischer, Tait, Chowdary, Collins (bib15) 2022; 6 Pocoski, Ma, Kessler, Boklage, Humphries (bib18) 2014; 20 Hay, Nissen, Pipe (bib31) 2021; 19 Shah, Stelzle, Lee, Beck, Alam, Clifford (bib28) 2018; 138 Dhingra, Vasan (bib3) 2012; 96 Jiménez-Yuste, Peyvandi, Klamroth, Castaman, Shanmukhaiah, Rangarajan (bib11) 2022; 6 (bib7) 2024 Kitazawa, Esaki, Tachibana, Ishii, Soeda, Muto (bib5) 2017; 117 Young, Liesner, Chang, Sidonio, Oldenburg, Jiménez-Yuste (bib12) 2019; 134 Curtis, Manco-Johnson, Konkle, Kulkarni, Wu, Baker (bib34) 2022; 13 Jiménez-Yuste, Peyvandi, Klamroth, Castaman, Shanmukhaiah, Rangarajan (bib37) 2022; 6 Jiménez-Yuste (10.1016/j.rpth.2024.102405_bib11) 2022; 6 Sharathkumar (10.1016/j.rpth.2024.102405_bib24) 2011; 17 Sood (10.1016/j.rpth.2024.102405_bib19) 2018; 2 Srivastava (10.1016/j.rpth.2024.102405_bib1) 2020; 26 Young (10.1016/j.rpth.2024.102405_bib12) 2019; 134 Misgav (10.1016/j.rpth.2024.102405_bib17) 2021; 27 Jiménez-Yuste (10.1016/j.rpth.2024.102405_bib37) 2022; 6 Doria (10.1016/j.rpth.2024.102405_bib39) 2015; 204 Van Der Valk (10.1016/j.rpth.2024.102405_bib15) 2022; 6 Mannucci (10.1016/j.rpth.2024.102405_bib33) 2009; 114 Garg (10.1016/j.rpth.2024.102405_bib30) 2011; 25 Curtis (10.1016/j.rpth.2024.102405_bib34) 2022; 13 Manco-Johnson (10.1016/j.rpth.2024.102405_bib38) 2017; 15 Fransen van de Putte (10.1016/j.rpth.2024.102405_bib26) 2013; 109 Shah (10.1016/j.rpth.2024.102405_bib28) 2018; 138 Howard (10.1016/j.rpth.2024.102405_bib40) 2021; 138 Shapiro (10.1016/j.rpth.2024.102405_bib27) 2022; 197 Kitazawa (10.1016/j.rpth.2024.102405_bib5) 2017; 117 Chang (10.1016/j.rpth.2024.102405_bib21) 2019; 82 Recht (10.1016/j.rpth.2024.102405_bib14) 2021; 5 Lenting (10.1016/j.rpth.2024.102405_bib6) 2017; 130 Pipe (10.1016/j.rpth.2024.102405_bib10) 2019; 6 Blair (10.1016/j.rpth.2024.102405_bib4) 2019; 79 Humphries (10.1016/j.rpth.2024.102405_bib20) 2018; 63 Franchini (10.1016/j.rpth.2024.102405_bib32) 2012; 7 Shapiro (10.1016/j.rpth.2024.102405_bib2) 2019; 184 Dhingra (10.1016/j.rpth.2024.102405_bib3) 2012; 96 Mahlangu (10.1016/j.rpth.2024.102405_bib9) 2018; 379 Faghmous (10.1016/j.rpth.2024.102405_bib25) 2019; 134 Chow (10.1016/j.rpth.2024.102405_bib35) 2013; 310 Négrier (10.1016/j.rpth.2024.102405_bib13) 2023; 10 Tuinenburg (10.1016/j.rpth.2024.102405_bib22) 2012; 32 Jenkins (10.1016/j.rpth.2024.102405_bib16) 2012; 157 Papadopoulos (10.1016/j.rpth.2024.102405_bib29) 2018; 31 Pocoski (10.1016/j.rpth.2024.102405_bib18) 2014; 20 (10.1016/j.rpth.2024.102405_bib7) 2024 Kempton (10.1016/j.rpth.2024.102405_bib23) 2021; 27 Callaghan (10.1016/j.rpth.2024.102405_bib36) 2021; 137 Oldenburg (10.1016/j.rpth.2024.102405_bib8) 2017; 377 Hay (10.1016/j.rpth.2024.102405_bib31) 2021; 19 |
References_xml | – volume: 6 start-page: e12837 year: 2022 ident: bib11 article-title: Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single-arm study (STASEY) publication-title: Res Pract Thromb Haemost contributor: fullname: Rangarajan – volume: 96 start-page: 87 year: 2012 end-page: 91 ident: bib3 article-title: Age as a risk factor publication-title: Med Clin North Am contributor: fullname: Vasan – volume: 138 start-page: 1100 year: 2018 end-page: 1112 ident: bib28 article-title: Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis publication-title: Circulation contributor: fullname: Clifford – volume: 82 start-page: 289 year: 2019 end-page: 294 ident: bib21 article-title: Obesity and overweight in patients with hemophilia: prevalence by age, clinical correlates, and impact on joint bleeding publication-title: J Chin Med Assoc contributor: fullname: Wang – volume: 130 start-page: 2463 year: 2017 end-page: 2468 ident: bib6 article-title: Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? publication-title: Blood contributor: fullname: Christophe – volume: 63 start-page: 329 year: 2018 end-page: 333 ident: bib20 article-title: Cardiovascular comorbidities in a United States patient population with hemophilia A: a comprehensive chart review publication-title: Adv Med Sci contributor: fullname: Lamerato – volume: 15 start-page: 2115 year: 2017 end-page: 2124 ident: bib38 article-title: Effect of late prophylaxis in hemophilia on joint status: a randomized trial publication-title: J Thromb Haemost contributor: fullname: Werk – volume: 310 start-page: 959 year: 2013 end-page: 968 ident: bib35 article-title: Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries publication-title: JAMA contributor: fullname: Avezum – volume: 17 start-page: 597 year: 2011 end-page: 604 ident: bib24 article-title: Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US) publication-title: Haemophilia contributor: fullname: Shapiro – volume: 109 start-page: 16 year: 2013 end-page: 23 ident: bib26 article-title: Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients publication-title: Thromb Haemost contributor: fullname: Collins – volume: 114 start-page: 5256 year: 2009 end-page: 5263 ident: bib33 article-title: How I treat age-related morbidities in elderly persons with hemophilia publication-title: Blood contributor: fullname: Mauser-Bunschoten – volume: 19 start-page: 6 year: 2021 end-page: 20 ident: bib31 article-title: Mortality in congenital hemophilia A – a systematic literature review publication-title: J Thromb Haemost contributor: fullname: Pipe – volume: 79 start-page: 1697 year: 2019 end-page: 1707 ident: bib4 article-title: Emicizumab: a review in haemophilia A publication-title: Drugs contributor: fullname: Blair – volume: 377 start-page: 809 year: 2017 end-page: 818 ident: bib8 article-title: Emicizumab prophylaxis in hemophilia A with inhibitors publication-title: N Engl J Med contributor: fullname: Young – volume: 134 start-page: 2127 year: 2019 end-page: 2138 ident: bib12 article-title: A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors publication-title: Blood contributor: fullname: Jiménez-Yuste – volume: 6 start-page: 902 year: 2022 end-page: 908 ident: bib15 article-title: Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study publication-title: Blood Adv contributor: fullname: Collins – volume: 27 start-page: 253 year: 2021 end-page: 260 ident: bib17 article-title: Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: real-world data publication-title: Haemophilia contributor: fullname: Bashari – volume: 117 start-page: 1348 year: 2017 end-page: 1357 ident: bib5 article-title: Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens publication-title: Thromb Haemost contributor: fullname: Muto – volume: 184 start-page: 712 year: 2019 end-page: 720 ident: bib2 article-title: Haemophilia and ageing publication-title: Br J Haematol contributor: fullname: Makris – volume: 204 start-page: W336 year: 2015 end-page: W347 ident: bib39 article-title: Diagnostic accuracy of ultrasound for assessment of hemophilic arthropathy: MRI correlation publication-title: AJR Am J Roentgenol contributor: fullname: Srivastava – volume: 31 start-page: 35 year: 2018 end-page: 41 ident: bib29 article-title: Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management publication-title: Ann Gastroenterol contributor: fullname: Deutsch – volume: 137 start-page: 2231 year: 2021 end-page: 2242 ident: bib36 article-title: Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies publication-title: Blood contributor: fullname: Lehle – volume: 379 start-page: 811 year: 2018 end-page: 822 ident: bib9 article-title: Emicizumab prophylaxis in patients who have hemophilia A without inhibitors publication-title: N Engl J Med contributor: fullname: Mancuso – volume: 134 start-page: 1133 year: 2019 ident: bib25 article-title: Estimating the risk of myocardial infarction in persons with hemophilia A using a machine-learning approach with US claims data publication-title: Blood contributor: fullname: Sima – volume: 6 year: 2022 ident: bib37 article-title: Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: a phase 3b, multicenter, single-arm study (STASEY) publication-title: Res Pract Thromb Haemost contributor: fullname: Rangarajan – volume: 7 start-page: 24 year: 2012 ident: bib32 article-title: Past, present and future of hemophilia: a narrative review publication-title: Orphanet J Rare Dis contributor: fullname: Mannucci – volume: 26 start-page: 1 year: 2020 end-page: 158 ident: bib1 article-title: WFH Guidelines for the management of hemophilia, 3rd edition publication-title: Haemophilia contributor: fullname: Pipe – volume: 5 year: 2021 ident: bib14 article-title: Emicizumab in obese adults with hemophilia A – pooled data from three phase III studies (HAVEN 1, 3 and 4) [abstract] publication-title: Res Pract Thromb Haemost contributor: fullname: Young – volume: 10 start-page: e168 year: 2023 end-page: e177 ident: bib13 article-title: Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study publication-title: Lancet Haematol contributor: fullname: Bernardi – year: 2024 ident: bib7 publication-title: Emicizumab US Medical Information Site – volume: 20 start-page: 472 year: 2014 end-page: 478 ident: bib18 article-title: Cardiovascular comorbidities are increased in U.S. patients with haemophilia A: a retrospective database analysis publication-title: Haemophilia contributor: fullname: Humphries – volume: 157 start-page: 653 year: 2012 end-page: 663 ident: bib16 article-title: Elevated factor VIII levels and risk of venous thrombosis publication-title: Br J Haematol contributor: fullname: O'Donnell – volume: 25 start-page: 135 year: 2011 end-page: 141 ident: bib30 article-title: Incidence and predictors of acute kidney injury in an urban cohort of subjects with HIV and hepatitis C virus coinfection publication-title: AIDS Patient Care STDs contributor: fullname: Tumilty – volume: 6 start-page: e295 year: 2019 end-page: e305 ident: bib10 article-title: Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study publication-title: Lancet Haematol contributor: fullname: Fukutake – volume: 13 start-page: 229 year: 2022 end-page: 241 ident: bib34 article-title: Comorbidities, health-related quality of life, health-care utilization in older persons with hemophilia-Hematology Utilization Group Study Part VII (HUGS VII) publication-title: J Blood Med contributor: fullname: Baker – volume: 138 start-page: 3186 year: 2021 ident: bib40 article-title: Evaluation of the safety of emicizumab prophylaxis in persons with hemophilia A: an updated summary of thrombotic events and thrombotic microangiopathies publication-title: Blood contributor: fullname: Nissen – volume: 32 start-page: 799 year: 2012 end-page: 804 ident: bib22 article-title: Coronary artery calcification in hemophilia A: no evidence for a protective effect of factor VIII deficiency on atherosclerosis publication-title: Arterioscler Thromb Vasc Biol contributor: fullname: Laros-van Gorkom – volume: 197 start-page: 397 year: 2022 end-page: 406 ident: bib27 article-title: Cardiovascular disease in hereditary haemophilia: the challenges of longevity publication-title: Br J Haematol contributor: fullname: Makris – volume: 27 start-page: 37 year: 2021 end-page: 45 ident: bib23 article-title: Management of comorbidities in haemophilia publication-title: Haemophilia contributor: fullname: Holme – volume: 2 start-page: 1325 year: 2018 end-page: 1333 ident: bib19 article-title: A cross-sectional analysis of cardiovascular disease in the hemophilia population publication-title: Blood Adv contributor: fullname: Shapiro – volume: 13 start-page: 229 year: 2022 ident: 10.1016/j.rpth.2024.102405_bib34 article-title: Comorbidities, health-related quality of life, health-care utilization in older persons with hemophilia-Hematology Utilization Group Study Part VII (HUGS VII) publication-title: J Blood Med contributor: fullname: Curtis – volume: 134 start-page: 2127 year: 2019 ident: 10.1016/j.rpth.2024.102405_bib12 article-title: A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors publication-title: Blood doi: 10.1182/blood.2019001869 contributor: fullname: Young – volume: 2 start-page: 1325 year: 2018 ident: 10.1016/j.rpth.2024.102405_bib19 article-title: A cross-sectional analysis of cardiovascular disease in the hemophilia population publication-title: Blood Adv doi: 10.1182/bloodadvances.2018018226 contributor: fullname: Sood – volume: 197 start-page: 397 year: 2022 ident: 10.1016/j.rpth.2024.102405_bib27 article-title: Cardiovascular disease in hereditary haemophilia: the challenges of longevity publication-title: Br J Haematol doi: 10.1111/bjh.18085 contributor: fullname: Shapiro – volume: 130 start-page: 2463 year: 2017 ident: 10.1016/j.rpth.2024.102405_bib6 article-title: Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? publication-title: Blood doi: 10.1182/blood-2017-08-801662 contributor: fullname: Lenting – volume: 6 start-page: e12837 year: 2022 ident: 10.1016/j.rpth.2024.102405_bib11 article-title: Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single-arm study (STASEY) publication-title: Res Pract Thromb Haemost doi: 10.1002/rth2.12837 contributor: fullname: Jiménez-Yuste – volume: 7 start-page: 24 year: 2012 ident: 10.1016/j.rpth.2024.102405_bib32 article-title: Past, present and future of hemophilia: a narrative review publication-title: Orphanet J Rare Dis doi: 10.1186/1750-1172-7-24 contributor: fullname: Franchini – volume: 6 year: 2022 ident: 10.1016/j.rpth.2024.102405_bib37 article-title: Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: a phase 3b, multicenter, single-arm study (STASEY) publication-title: Res Pract Thromb Haemost doi: 10.1002/rth2.12837 contributor: fullname: Jiménez-Yuste – volume: 32 start-page: 799 year: 2012 ident: 10.1016/j.rpth.2024.102405_bib22 article-title: Coronary artery calcification in hemophilia A: no evidence for a protective effect of factor VIII deficiency on atherosclerosis publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/ATVBAHA.111.238162 contributor: fullname: Tuinenburg – volume: 5 issue: Suppl 2 year: 2021 ident: 10.1016/j.rpth.2024.102405_bib14 article-title: Emicizumab in obese adults with hemophilia A – pooled data from three phase III studies (HAVEN 1, 3 and 4) [abstract] publication-title: Res Pract Thromb Haemost contributor: fullname: Recht – volume: 19 start-page: 6 issue: Suppl 1 year: 2021 ident: 10.1016/j.rpth.2024.102405_bib31 article-title: Mortality in congenital hemophilia A – a systematic literature review publication-title: J Thromb Haemost doi: 10.1111/jth.15189 contributor: fullname: Hay – volume: 379 start-page: 811 year: 2018 ident: 10.1016/j.rpth.2024.102405_bib9 article-title: Emicizumab prophylaxis in patients who have hemophilia A without inhibitors publication-title: N Engl J Med doi: 10.1056/NEJMoa1803550 contributor: fullname: Mahlangu – volume: 109 start-page: 16 year: 2013 ident: 10.1016/j.rpth.2024.102405_bib26 article-title: Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients publication-title: Thromb Haemost doi: 10.1160/TH12-05-0332 contributor: fullname: Fransen van de Putte – volume: 63 start-page: 329 year: 2018 ident: 10.1016/j.rpth.2024.102405_bib20 article-title: Cardiovascular comorbidities in a United States patient population with hemophilia A: a comprehensive chart review publication-title: Adv Med Sci doi: 10.1016/j.advms.2018.06.001 contributor: fullname: Humphries – volume: 138 start-page: 1100 year: 2018 ident: 10.1016/j.rpth.2024.102405_bib28 article-title: Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.117.033369 contributor: fullname: Shah – volume: 6 start-page: 902 year: 2022 ident: 10.1016/j.rpth.2024.102405_bib15 article-title: Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study publication-title: Blood Adv doi: 10.1182/bloodadvances.2021005260 contributor: fullname: Van Der Valk – volume: 137 start-page: 2231 year: 2021 ident: 10.1016/j.rpth.2024.102405_bib36 article-title: Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies publication-title: Blood doi: 10.1182/blood.2020009217 contributor: fullname: Callaghan – volume: 15 start-page: 2115 year: 2017 ident: 10.1016/j.rpth.2024.102405_bib38 article-title: Effect of late prophylaxis in hemophilia on joint status: a randomized trial publication-title: J Thromb Haemost doi: 10.1111/jth.13811 contributor: fullname: Manco-Johnson – volume: 79 start-page: 1697 year: 2019 ident: 10.1016/j.rpth.2024.102405_bib4 article-title: Emicizumab: a review in haemophilia A publication-title: Drugs doi: 10.1007/s40265-019-01200-2 contributor: fullname: Blair – volume: 157 start-page: 653 year: 2012 ident: 10.1016/j.rpth.2024.102405_bib16 article-title: Elevated factor VIII levels and risk of venous thrombosis publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2012.09134.x contributor: fullname: Jenkins – volume: 96 start-page: 87 year: 2012 ident: 10.1016/j.rpth.2024.102405_bib3 article-title: Age as a risk factor publication-title: Med Clin North Am doi: 10.1016/j.mcna.2011.11.003 contributor: fullname: Dhingra – volume: 20 start-page: 472 year: 2014 ident: 10.1016/j.rpth.2024.102405_bib18 article-title: Cardiovascular comorbidities are increased in U.S. patients with haemophilia A: a retrospective database analysis publication-title: Haemophilia doi: 10.1111/hae.12339 contributor: fullname: Pocoski – volume: 82 start-page: 289 year: 2019 ident: 10.1016/j.rpth.2024.102405_bib21 article-title: Obesity and overweight in patients with hemophilia: prevalence by age, clinical correlates, and impact on joint bleeding publication-title: J Chin Med Assoc doi: 10.1097/JCMA.0000000000000047 contributor: fullname: Chang – volume: 31 start-page: 35 year: 2018 ident: 10.1016/j.rpth.2024.102405_bib29 article-title: Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management publication-title: Ann Gastroenterol contributor: fullname: Papadopoulos – volume: 26 start-page: 1 issue: suppl 6 year: 2020 ident: 10.1016/j.rpth.2024.102405_bib1 article-title: WFH Guidelines for the management of hemophilia, 3rd edition publication-title: Haemophilia doi: 10.1111/hae.14046 contributor: fullname: Srivastava – volume: 184 start-page: 712 year: 2019 ident: 10.1016/j.rpth.2024.102405_bib2 article-title: Haemophilia and ageing publication-title: Br J Haematol doi: 10.1111/bjh.15745 contributor: fullname: Shapiro – volume: 204 start-page: W336 year: 2015 ident: 10.1016/j.rpth.2024.102405_bib39 article-title: Diagnostic accuracy of ultrasound for assessment of hemophilic arthropathy: MRI correlation publication-title: AJR Am J Roentgenol doi: 10.2214/AJR.14.12501 contributor: fullname: Doria – volume: 6 start-page: e295 year: 2019 ident: 10.1016/j.rpth.2024.102405_bib10 article-title: Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study publication-title: Lancet Haematol doi: 10.1016/S2352-3026(19)30054-7 contributor: fullname: Pipe – volume: 138 start-page: 3186 issue: Suppl 1 year: 2021 ident: 10.1016/j.rpth.2024.102405_bib40 article-title: Evaluation of the safety of emicizumab prophylaxis in persons with hemophilia A: an updated summary of thrombotic events and thrombotic microangiopathies publication-title: Blood doi: 10.1182/blood-2021-146147 contributor: fullname: Howard – volume: 27 start-page: 253 year: 2021 ident: 10.1016/j.rpth.2024.102405_bib17 article-title: Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: real-world data publication-title: Haemophilia doi: 10.1111/hae.14261 contributor: fullname: Misgav – volume: 134 start-page: 1133 issue: Suppl 1 year: 2019 ident: 10.1016/j.rpth.2024.102405_bib25 article-title: Estimating the risk of myocardial infarction in persons with hemophilia A using a machine-learning approach with US claims data publication-title: Blood doi: 10.1182/blood-2019-123761 contributor: fullname: Faghmous – volume: 310 start-page: 959 year: 2013 ident: 10.1016/j.rpth.2024.102405_bib35 article-title: Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries publication-title: JAMA doi: 10.1001/jama.2013.184182 contributor: fullname: Chow – volume: 27 start-page: 37 issue: Suppl 3 year: 2021 ident: 10.1016/j.rpth.2024.102405_bib23 article-title: Management of comorbidities in haemophilia publication-title: Haemophilia doi: 10.1111/hae.14013 contributor: fullname: Kempton – volume: 25 start-page: 135 year: 2011 ident: 10.1016/j.rpth.2024.102405_bib30 article-title: Incidence and predictors of acute kidney injury in an urban cohort of subjects with HIV and hepatitis C virus coinfection publication-title: AIDS Patient Care STDs doi: 10.1089/apc.2010.0104 contributor: fullname: Garg – year: 2024 ident: 10.1016/j.rpth.2024.102405_bib7 – volume: 10 start-page: e168 year: 2023 ident: 10.1016/j.rpth.2024.102405_bib13 article-title: Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study publication-title: Lancet Haematol doi: 10.1016/S2352-3026(22)00377-5 contributor: fullname: Négrier – volume: 117 start-page: 1348 year: 2017 ident: 10.1016/j.rpth.2024.102405_bib5 article-title: Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens publication-title: Thromb Haemost doi: 10.1160/TH17-01-0030 contributor: fullname: Kitazawa – volume: 114 start-page: 5256 year: 2009 ident: 10.1016/j.rpth.2024.102405_bib33 article-title: How I treat age-related morbidities in elderly persons with hemophilia publication-title: Blood doi: 10.1182/blood-2009-07-215665 contributor: fullname: Mannucci – volume: 377 start-page: 809 year: 2017 ident: 10.1016/j.rpth.2024.102405_bib8 article-title: Emicizumab prophylaxis in hemophilia A with inhibitors publication-title: N Engl J Med doi: 10.1056/NEJMoa1703068 contributor: fullname: Oldenburg – volume: 17 start-page: 597 year: 2011 ident: 10.1016/j.rpth.2024.102405_bib24 article-title: Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US) publication-title: Haemophilia doi: 10.1111/j.1365-2516.2010.02463.x contributor: fullname: Sharathkumar |
SSID | ssj0002022025 |
Score | 2.3028653 |
Snippet | The treatment of older people with hemophilia A (HA) can be complicated by comorbidities.
This post hoc analysis evaluates the efficacy and safety of... BackgroundThe treatment of older people with hemophilia A (HA) can be complicated by comorbidities.ObjectivesThis post hoc analysis evaluates the efficacy and... • Older people with hemophilia A may have other diseases at the same time (comorbidities). • This analysis addresses the data gap of emicizumab in people with... |
SourceID | pubmedcentral proquest crossref pubmed elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 102405 |
SubjectTerms | comorbidities comorbidity emicizumab hemophilia A Original prophylaxis |
Title | Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials |
URI | https://dx.doi.org/10.1016/j.rpth.2024.102405 https://www.ncbi.nlm.nih.gov/pubmed/38783987 https://www.proquest.com/docview/3060379827/abstract/ https://pubmed.ncbi.nlm.nih.gov/PMC11112372 |
Volume | 8 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NTtwwELaAUy9VUf-2BTSVeqvCem0njrkhBGIrUfVQJG6W7djaoCYb7S4H-gY8CC_WJ-k4ThC0VQ-VcopjyfGM58f-_A0hH3PPgpOYpgrrikxUIWQqcJcFNgsm0sOUfW3Aiy_F-aX4fJVfbZFivAvTg_adrQ_b781hWy96bGXXuOmIE5t-vTiJy5xxyabbZFty_ihHv-6P1hg--XBDJoG5Vt0mnjwwEakKRKxV93cv9GeU-TtY8pH3OXtBng9hIxyn4e2SLd--JLenTe3qHzeNsVCvwUc2COMiqBXqFhI2HOJGKyx8s-zi1omB4_QGFW25snXVE6oCGpUKft7d5xRuUfXXR2AGshJYBhDQLdDZwXw-h77Kx_oVuTw7_XZyng2lFDKHGdsmM6aUla0qRTlGINwGalj0_TTQoNBDexp4mHkmrDVWmkBpVRgVvCzkzLlQ8ddkp122_i0BZ0VQIhqnUgm0F9Yqb9AOWInJkfNmQj6NU6u7xJihRyjZtY6C0FEQOgliQvJx9vXg85Mv12jS_9nvwygqjQsinnKY1uMEa8yBKJeqZHJC3iTRPYyD46C5KrGlfCLUhw8i2fbTFtTBnnR71Ll3_9_1PXkW_yAh2PbIzmZ14_cxpNnYg34r4KDX41_YZ_xa |
link.rule.ids | 230,315,733,786,790,870,891,27955,27956,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELZKOcClgPjb_oCRuKHsZm0njrlVVatd6FYcWtGbZTu2NqXJRrvZQ_sGPAgvxpMwjpOqLQgJpJziWLIzM54Z-_M3CL1PLHGGQ5rKtEkjljsXCUdN5MjYKU8Pk7W1AWcn6eSMfTpPzjdQ2t-FaUH7RhfD6rIcVsW8xVbWpRn1OLHRl9mBN3NCORk9QA_BYElyK0u_aA_XCDxJd0cmwLmWdePPHgjzZAXMV6v7sx_6Pc68D5e85X-OnqCv_cgD7OTbcN3oobm-R-r471N7ira6kBTvh_ZnaMNWz9HVYVmY4npdKo2LFbaeaUIZD5jFRYUD7hz7TVw8t-Wi9tsyCu-HN6DEi6Uu8pasFcOCleOf338kMb4Cs1p9xKojQsELhxmu5-BI8XQ6xW0FkdULdHZ0eHowiboyDZGBbLCJlMp4rvNcxBSiG6pdrIiPK2IXOwHe38aOurElTGuluXJxnKdKOMtTPjbG5fQl2qwWlX2NsNHMCeYXvkwwWIu0FlbBGqM5JF7GqgH60AtN1oGNQ_YwtQvpRSy9iGUQ8QAlvVxlF0-EOEGCu_hrv3e9EkgwNn-CoioLP1hCfhVTLjLCB-hVUIqbcVAYNBUZtGR31OXmA0_kfbcFlKAl9O6Fvv3_Xd-iR5PT2bE8np583kGP_WwCUm4XbTbLtd2D0KnRb1o7-QU3HR2N |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFLWgSIgNFPHoQAtGYocyk7GdccyuKh11gFZdUKkSC8tPTQrJRDOZRfsHfAg_xpf0Ok6qtiAWlbKKbcnOffhe--RchN5njnjDIU1l2kwSZr1PhKcm8WTsVaCHydvagIdHk4MT9vk0O-1QlasOVlkZXQyrn-WwKuYttrIuzajHiY2OD_eCmRPKyai2fnQfPQCjJfxapn7WXrAReLLuP5kI6VrWTbh_ICwQFrBQse7fe9HfseZtyOS1PWj6BH3vZx-hJz-G60YPzcUtYse7LW8TPe5CU7wb-zxF91z1DJ3vl4UpLtal0rhYYRcYJ5QJwFlcVDjiz3E4zMVzVy7qcDyj8G58A8q8WOrCtqStGByXxX9-_c5SfA7mtfqIVUeIghceM1zPYUPFs9kMt5VEVs_RyXT_295B0pVrSAxkhU2iVM6ttlakFKIcqn2qSIgvUp96AVGASz31Y0eY1kpz5dPUTpTwjk_42Bhv6Qu0US0qt4Ww0cwLFhxgLhj4JK2FU-BrNIcEzDg1QB96wck6snLIHq52JoOYZRCzjGIeoKyXreziihgvSNg2_jvuXa8IEowu3KSoysEHlpBnpZQL0LoBehkV42oeFCZNRQ4t-Q2VueoQCL1vtoAitMTeveBf3X3oW_Tw-NNUfp0dfXmNHoXFRMDcNtpolmu3AxFUo9-0pnIJBtcgDQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Emicizumab+is+efficacious+in+people+with+hemophilia+A+with+comorbidities+aged+%E2%89%A550+years%3A+analysis+of+4+phase+III+trials&rft.jtitle=Research+and+practice+in+thrombosis+and+haemostasis&rft.au=Jim%C3%A9nez-Yuste%2C+V%C3%ADctor&rft.au=Oldenburg%2C+Johannes&rft.au=Tzeng%2C+Eunice&rft.au=Lim%2C+Elise&rft.date=2024-03-01&rft.pub=Elsevier+Inc&rft.issn=2475-0379&rft.eissn=2475-0379&rft.volume=8&rft.issue=3&rft_id=info:doi/10.1016%2Fj.rpth.2024.102405&rft.externalDocID=S2475037924000943 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2475-0379&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2475-0379&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2475-0379&client=summon |